The current invention relates to systems and methods for adhering tubular structures within the body, such as vessels.
The devices, systems, and methods described here may be used to enhance mechanical adhesion between tubular structures within the body. In some instances, this may be desirable to improve mechanical adhesion between tubular structures used to form fistulas. A fistula is generally a passageway formed between two internal organs. Forming a fistula between two tubular structures, such as blood vessels, can have one or more beneficial functions. For example, the formation of a fistula between an artery and a vein may provide access to the vasculature for hemodialysis patients. Specifically, forming a fistula between an artery and a vein allows blood to flow quickly between the vessels while bypassing the capillaries. In other instances, a fistula may be formed between two veins to form a veno-venous fistula. Generally, fistula formation requires surgical dissection of a target vein, and transecting and moving the vein for surgical anastomosis to the artery. It may therefore be useful to find improved ways to form a fistula between two blood vessels.
Described here are devices, systems, and methods for adhering two or more tubular structures together. The tubular structures may be any suitable tubular structure, such as an artery, vein, duct, digestive tract, and so forth. For example, the devices, systems, and methods disclosed herein may increase mechanical adhesion between two blood vessels such as an artery and a vein, a vein and a vein, an artery and an artery, or between a duct and a duct, a digestive tract and a digestive tract, and the like.
Generally, a method for adhering tubular structures described herein comprises advancing a first catheter into a first tubular structure and a second catheter into a second tubular structure. The first catheter may comprise a first adhesion element and the second catheter may comprise a second adhesion element. The first adhesion element may be aligned with the second adhesion element. The first and second tubular structures may be adhered by heating tissue between the two adhesion elements.
In some variations, a method of adhering vessels together comprises advancing a first catheter comprising a first magnetic adhesion element into a first blood vessel and a second catheter comprising a second magnetic adhesion element into a second blood vessel. The first magnetic adhesion element may be aligned with the second magnetic adhesion element. In some variations, the first magnetic adhesion element may be aligned with the second magnetic adhesion element by fluoroscopically visualizing at least a portion of the first and second catheters. In some variations, the first and/or second catheters may comprise one or more rotational indicators. The rotational indicators may be fluoroscopically visualized to align the catheters. Tissue of the first and second blood vessels may be compressed between the first and second magnetic adhesion elements. An adhesion (weld) may be formed between the first blood vessel to the second blood vessel by using the magnetic adhesion elements to heat tissue of the first and second blood vessels between the magnetic adhesion elements. In some variations, the tissue may be heated by delivery of radiofrequency energy from the magnetic adhesion elements. In other variations, the tissue may be heated by ohmic heating of the magnetic adhesion elements. In these variations the magnetic adhesion elements may comprise a resistor. Heating may occur over a single cycle, or a plurality of cycles. In some variations, impedance between the magnetic adhesion elements may be monitored before, after, or during energy delivery. Additionally or alternatively, tissue temperature may be monitored before, after, or during energy delivery. In some variations, a second adhesion may be formed between the first blood vessel and the second blood vessel. The formed adhesion(s) may in some instances have a width between about 0.1 mm and about 15 mm, and a length between about 0.1 mm and about 10 cm. In some variations, a fistula may be formed through the adhesion. For example, a fistula may be formed through the adhesion using the magnetic adhesion elements.
In some variations, a system for adhering two tubular structures together comprises a first catheter comprising a first adhesion element and a second catheter comprising a second adhesion element. The first adhesion element may be magnetic and may comprise a flat contact surface. The second adhesion element may be magnetic and comprise a flat contact surface. A power source may be connected to the first and second adhesion elements. In some variations, the first adhesion element may be located at a distal end of the first catheter, and the second adhesion element may be located at a distal end of the second catheter. The first and/or second adhesion elements may be coated with one or more layers of a fluoropolymer. Additionally or alternatively, the first and/or second magnetic adhesion elements may comprise surface insulation. In some variations, the first adhesion element may define a recess. In some of these variations, the second adhesion element may comprise a protrusion complementary to the recess. In some variations, the first and/or second catheter may comprise a rotational indicator.
In some variations, the first catheter may comprise a proximal portion and a distal portion, wherein the largest cross-sectional dimension of the distal portion is larger than the largest cross-sectional dimension of the proximal portion. The first adhesion element may be located on the distal portion. Additionally or alternatively, the second catheter may comprise a proximal portion and a distal portion, wherein the largest cross-sectional dimension of the distal portion is larger than the largest cross-sectional dimension of the proximal portion. The second adhesion element may be located on the distal portion. In some variations, at least one of the pushability, flexibility, or torquability of the first and/or second catheter may be adjustable. For example, the first catheter may comprise a distal portion, an inner proximal portion, and an outer proximal portion. The outer proximal portion may be slidable relative to the distal portion. The distal portion may have a retracted configuration and an extended configuration. The distal portion may be configured to extend away from the outer proximal portion when moved from the retracted configuration to the extended configuration.
Generally described here are devices, systems, and methods for increasing mechanical adhesion between tubular structures, such as blood vessels, and in some instances forming a weld between the structures to adhere the two structures together. Generally, to adhere two tubular structures together, a system comprising multiple catheters may be advanced in a minimally invasive fashion (e.g., for blood vessels, via the vasculature) to a target location and used to adhere the tubular structures together. In some examples, the tubular structures may comprise blood vessels such as two arteries, two veins, or a vein and an artery.
Generally, each catheter may comprise an adhesion element. An adhesion element may comprise an element capable of adhering tissue, either alone or in combination with another adhesion element. An adhesion element may be configured to adhere tissue together by heating the tissue. In some variations, an adhesion element may heat issue by delivering electrical energy to the tissue. In some of these variations, the adhesion element may comprise a magnet configured to heat tissue by delivering electrical current, as described in more detail herein. In other variations, an adhesion element may be heated through resistive heating, which may in turn heat tissue. In yet other variations, an adhesion element may heat tissue using laser energy. For example, a catheter may comprise a fiber optic filament coupled to a laser, such that the adhesion element may be configured to direct laser energy to heat tissue. In yet another variation, an adhesion element may deliver ultrasonic energy to heat tissue. In such a variation, the adhesion element may comprise a piezoelectric element configured to use ultrasonic vibration to induce heating.
A first catheter comprising an adhesion element may be placed at a target location in a first tubular structure, and a second catheter comprising an adhesion element may be placed at a target location in a second tubular structure. The catheters may be aligned relative to each other using the adhesion elements, coaption regions, and/or visual alignment aids, as described in more detail herein. For example, when the tubular structures are blood vessels, a first catheter may be placed in a first blood vessel, and a second catheter may be placed in a second blood vessel, where the first and second vessels are in proximity to each other, and the two catheters may be aligned to coapt the two vessels. Tissue heating due to one or more adhesion elements may adhere tissue of the first tubular structure to tissue of the second tubular structure. For example, current applied to blood vessel walls may denature proteins in each vessel, which may cause them to adhere together. Adhesion may be performed before, during, or after other procedures, such as fistula formation, as described in more detail herein.
I. Systems
Generally, the systems described here are configured to adhere tubular structures in the body, such as blood vessels. In some variations, the systems comprise two catheters each comprising one or more adhesion elements. An adhesion element may comprise an element capable of adhering tissue, either alone or in combination with another adhesion element, and may be configured to adhere tissue together by heating the tissue. In some variations, an adhesion element may heat issue by delivering electrical current to the tissue, while in other variations an adhesion element may heat tissue by delivering laser or ultrasonic energy to the tissue. In yet other variations, an adhesion element may be resistively heated, which may in turn heat tissue. In some variations, an adhesion element may comprise a magnet configured to deliver energy to tissue, although in other variations it may comprise a non-magnetic element.
The adhesion elements may be configured to be delivered to target locations in tubular structures (e.g., blood vessels) via catheters. When an adhesion element is configured to heat tissue by delivering electrical energy, it may comprise a contact surface configured to contact tissue (e.g., a blood vessel wall) or fluid (e.g., blood). When the contact surface is in contact with tissue and/or fluid at the target location, it may supply current to and/or carry current from the tissue and/or fluid. This may result in heat, which in turn may facilitate adhesion of one portion of tissue to another. More particularly, current applied to the adhesion elements may be configured to heat and/or desiccate tissue to mechanically adhere the vessels together through protein denaturation. In some instances, tissue may be thermally welded together by applying a coagulation current to an electrode to denature connective tissue proteins and thereby increase adhesion between tissue planes. In some instances, the denatured proteins from each vessel may intertwine to fuse together and/or shrink the vessel. In some variations, thermal denaturing and welding may modify the vessel without removing material as occurs when ablating tissue.
In some variations, the adhesion elements (102, 106) may each deliver electrical energy to heat tissue. For example, each adhesion elements (102, 106) may be connected to an active output of the power supply (110) to deliver current and thus heat adjacent tissue. As such, the adhesion elements (102, 106) may simultaneously heat tissue from opposing sides. A ground pad (e.g., a large metal plate or flexible metalized pad) affixed to the patient may be connected to a return terminal of the power supply. In other variations, the first adhesion element (102) may be connected to the active output of the power supply (110) and the second adhesion element (106) may be connected to the return terminal. In yet other variations, the first adhesion element (102) may be connected to an output of the power supply, and the second adhesion element (106) may be floating, that is, not directly connected to any output of the power supply, in a focused monopolar configuration.
It should be appreciated that in other variations, only the first catheter may be connected to the power supply in a monopolar configuration. For example, only the first adhesion element may heat tissue, while the second adhesion element may mechanically contribute to tissue adhesion by pressing tissue toward the first adhesion element while the first adhesion element heats tissue. In such a configuration, the first adhesion element may be connected to an active output of a power supply, and a ground pad affixed to the patient may be connected to a return terminal of the power supply. The second adhesion element may not be connected to the power supply but may oppose the first adhesion element and compress tissue between the two adhesion elements, promoting heating and adhesion.
The catheters and adhesion elements may be configured to coapt with each other and to compress tissue between the adhesion elements in order to adhere tissue when it is heated. In some instances, a system may comprise first and second catheters each having one or more magnets, such that magnets of the first catheter may be attracted to magnets of the second catheter to bring the catheters in closer approximation. In some variations, the adhesion elements themselves may be magnets and may be configured to be attracted to each other. As such, the adhesion elements may promote axial and/or rotational alignment of the catheters. Additionally or alternatively, the catheters may comprise coaption regions comprising magnets, and/or may comprise one or more visual alignment aids, to promote tissue coaption as well as axial and/or rotational alignment of the catheters. For instance, a rotational indicator may allow catheter alignment to be visualized under fluoroscopy, such that a user may manipulate the catheters into a desired position. In some variations, the catheters may also be configured to promote the ability of an adhesion element to press into tissue, as described in more detail herein. The catheters may have the same configuration of elements, or may have different and/or complementary configurations of elements.
The adhesion elements (202, 208) may comprise a conductive material and may be connected to a power supply configured to provide electrical current for heating tissue.
When heat is applied to the compressed vessels using the devices, systems, and methods described herein, heating tissue to 70° C. may result in denaturation. In some variations, the delivered energy may be constant, while in other variations it may be modulated. In some variations, the tissue may be heated by the delivery of radiofrequency energy to tissue. The power source may deliver energy having any suitable waveform to the tissue via the adhesion elements, such as but not limited to waveform having a sinusoidal or square shape. Electrical energy delivered to tissue may have a peak voltage below the ionization threshold of the tissue. For example, when the waveform is a sinusoidal waveform, the peak voltage may in some variations be below about 150 V. It should also be appreciated that in other variations, current need not travel through tissue in order to heat the tissue. For example, the tissue may be heated through ohmic heating of the adhesion elements. For example, each adhesion element may comprise a resistor resulting in ohmic heating. In these instances, either AC or DC current may be used. In yet other variations, the tissue may be heated through laser or ultrasonic energy delivery.
In some variations, one or more surfaces of an adhesion element may be coated with a material that may facilitate removal of the adhesion element from a tissue surface after heating. For example, one or more surfaces of an adhesion element may be coated with one or more layers of PTFE, parylene, silicone, or another fluoropolymer.
Generally, catheters in the coapted state, as shown in
However, in other variations, the adhesion elements may not comprise flat contact surfaces. For example,
The adhesion elements described herein may be attached to catheters, as shown for example in
In other variations, the catheters described herein may be configured to promote the ability of an adhesion element to press into tissue. For example, the adhesion element may be located on a portion of a catheter having a greater diameter than an adjacent portion of a catheter. This may allow the contact surfaces of the adhesion elements to more easily contact tissue. For example,
In some variations, the catheters described herein may be configured to have adjustable stiffness, for example in the event that an increase in pushability, flexibility, or torquability may be desired. For example,
In
Furthermore, in other variations, an adhesion element need not comprise a magnet. While magnetic adhesion elements may help to compress tissue between two catheters, in some variations the adhesion elements may comprise any material suitable for heating tissue to cause adhesion. For example, the adhesion elements may comprise any suitable conductive material. In some of these variations, the catheters described herein may comprise one or more adhesion elements and one or more separate alignment features to assist in coaption and rotational and/or axial alignment of the catheters relative to each other. In some of these variations, alignment features may assist a user in manual positioning of the catheters. Generally, in these variations, the catheters may comprise at least one of a flat coaption surface, a magnet, and a rotational indicator. Combinations of one or more of these elements may improve the ability of a user to orient and align catheters rotationally. For instance, the catheters described herein may comprise one or more adhesion elements and a separate coaption region comprising one or more magnets to promote coaption and alignment. For example, a catheter may comprise a magnet and a separate adhesion element comprising an electrode.
It should be appreciated that the catheters of the systems described here may comprise one or more magnets, and each catheter may comprise any number of individual magnets (e.g., one, two, three, four, five, six, seven, or eight or more, etc.). In some variations in which a catheter comprises multiple magnets, one or more magnets may act as adhesion elements and be configured to heat tissue (e.g., through delivery of electrical current), while one or more other magnets may not be configured to heat tissue. In variations in which a catheter comprises a plurality of magnets, these magnets may be grouped into one or more magnet arrays. The magnets may be located inside and/or outside of a catheter body. The magnets may be positioned at any suitable location along the length of the catheter. Generally, the dimensions of the magnets described herein may be selected based on the size of the catheters carrying the magnets, which in turn may be selected based on the anatomical dimensions of the blood vessels through which the catheters may be advanced. For example, if the catheter is to be advanced through a blood vessel having an internal diameter of about 3 mm, it may be desirable to configure any magnet to be less than about 3 mm at the widest part of its cross-section, to reduce the risk of injury to vessel walls during advancement and manipulation of the catheter. Each magnet may have any suitable length (e.g., about 5 mm, about 10 mm, about 15 mm, about 20 mm, or the like), although it should be appreciated that in some instances longer magnets may limit the flexibility of the catheter to maneuver through tissue.
The magnets described here throughout may be permanent magnets comprising one or more hard magnetic materials, such as but not limited to alloys of rare earth elements (e.g., samarium-cobalt magnets or neodymium magnets, such as N52 magnets) or alnico. In some variations, the magnets may comprise anisotropic magnets; in other variations, the magnets may comprise isotropic magnetics. In some variations, the magnets may be formed from compressed powder. In some variations, a portion of the magnets (e.g., a permeable backing) may comprise one or more soft magnetic materials, such as but not limited to iron, cobalt, nickel, or ferrite. When the magnets are configured to deliver electrical current to tissue, the magnets may comprise conductive material and/or comprise a conductive coating. When the magnets are located within the catheter, as in
It should be appreciated that while some of the systems described here comprise a first catheter and a second catheter each comprising one or more permanent magnets (which may or may not be configured to heat tissue), in other variations either the first or second catheter may comprise ferromagnetic elements (i.e., elements attracted to but not generating a permanent magnetic field). For example, in some variations, the first catheter may include only one or more ferromagnetic elements while the second catheter comprises one or more permanent magnets. In other variations, the second catheter may include only one or more ferromagnetic elements while the first catheter comprises one or more permanent magnets. However, in other variations, one or both of the first and second catheters may include any suitable combination of ferromagnetic, permanent, and/or other suitable kinds of magnets.
Returning to
The systems described herein may further comprise one or more additional alignment features to help ensure that the catheters are axially and/or rotationally aligned prior to heating the tissue to achieve adhesion. For example, one or both of the first and second catheters may comprise a visual alignment aid for indirectly visualizing the alignment of a catheter within a tubular structure or relative to another catheter, such as via fluoroscopy, during positioning and/or alignment thereof.
In some variations, the visual alignment aid may comprise a rotational indicator. A rotational indicator may serve as a visual marker for guiding rotational alignment of two catheters as viewed under fluoroscopy. The rotational indicators of each catheter may be used to rotationally and/or axially position the catheters such that that one or more adhesion elements are properly positioned to adhere tissue. Generally, a rotational indicator may be configured such that its rotational orientation is discernable in a two-dimensional fluoroscopic image. A rotational indicator may comprise a radiopaque portion. The first catheter may include a first radiopaque portion and the second catheter may include a corresponding second radiopaque portion. An X-ray beam may fluoroscopically image an orientation of the first radiopaque portion and the second radiopaque portion, and the image may be shown on a display for a user. The user may then manipulate one or both of the catheters to align the catheters. A rotational indicator may be provided along any suitable portion of the catheter. In some variations, the rotational indicator may comprise any radiopaque metal, such as tungsten, platinum iridium, stainless steel, titanium, as well as a tungsten filled polymer, zirconia ceramic, or any suitable radiopaque material. In some variations, the rotational indicator may comprise a radiopaque film Rotational indicators suitable for use in the catheters described herein are discussed in more detail in U.S. patent application Ser. No. 15/406,755, filed Jan. 15, 2017, titled “DEVICES AND METHODS FOR FORMING A FISTULA” and claiming the benefit of U.S. Provisional Application No. 62/399,471, filed Sep. 25, 2016, and U.S. Provisional Application No. 62/279,603, filed Jan. 15, 2016, which is hereby incorporated by reference in its entirety.
II. Methods
Also described here are methods for adhering tissue of two tubular structures, such as two blood vessels. When the tubular structures comprise blood vessels, the two blood vessels may be two closely-associated blood vessels, such as a vein and an artery, two veins, two arteries, or the like. Generally, when the tubular structures are blood vessels, the methods described here comprise accessing a first blood vessel with a first catheter having features as described herein, and advancing the first catheter to a target location within the first blood vessel. A second blood vessel may be accessed with a second catheter having features as described herein, and the second catheter may be advanced to a target location within the second vessel. After the vessels are brought toward each other and aligned, one or more adhesion elements may be activated to heat and denature tissue to fuse tissue together and form an adhesion between the two vessels. The catheters may then be removed. In some variations, a fistula may be formed through a portion of the welded tissue. In some instances, a fistula may be formed using the devices, systems, and methods in U.S. patent application Ser. No. 13/298,169, filed on Nov. 16, 2011, and titled “DEVICES AND METHODS FOR FORMING A FISTULA,” which is hereby incorporated by reference in its entirety, and in U.S. patent application Ser. No. 15/406,755, filed Jan. 15, 2017, titled “DEVICES AND METHODS FOR FORMING A FISTULA” and claiming the benefit of U.S. Provisional Application No. 62/399,471, filed Sep. 25, 2016, and U.S. Provisional Application No. 62/279,603, filed Jan. 15, 2016, which was previously incorporated by reference in its entirety, while in other variations, the devices and systems described herein may be used to form a fistula.
When the tubular structures are blood vessels, advancement of one or more catheters through a vessel to a target site is not particularly limited. In some variations, a first catheter is advanced into an artery, and a second catheter is advanced into a vein. In other variations, a first catheter is advanced into a first vein, and a second catheter is advanced into a second vein. In still other variations, a first catheter is advanced into a first artery and a second catheter is advanced into a second artery. In some variations, a first catheter is advanced into a vein, and the second catheter is advanced into an artery. The first and/or second catheters may be advanced over a guidewire or in any suitable manner and may or may not occur under indirect visualization (e.g., via fluoroscopy, X-ray, or ultrasound).
In some variations, each of the first or second catheters may comprise one or more adhesion elements as described herein. The adhesion elements may or may not be magnetic. In some variations, aligning the first and second catheters may comprise axial and/or rotational alignment of the adhesion elements. In variations where both the first and second catheters comprise adhesion elements, the catheters may be oriented to align these adhesion elements. The catheters may be aligned in any suitable manner. In some variations, magnetic adhesion elements may generate an attractive force between the first and second catheters, which may pull the catheters toward each other. In these or other variations, separate coaption regions may comprise one or more magnets configured to generate an attracted force between the first and second catheters.
Additionally or alternatively, the catheter systems described herein may comprise one or more rotational indicators allowing for indirect visualization of catheter alignment such as through fluoroscopy. In variations where the first and/or second catheters comprise one or more rotational indicators, such as those described herein, the markers may be viewed (e.g., via fluoroscopy, X-ray, or the like) to ensure that the catheters have the proper axial and/or radial orientation relative to each other. For example, the catheter and rotational indicators may be visualized fluoroscopically during alignment of the catheters, and in some cases from at least advancement steps through alignment of the catheters. The user may view the rotational indicators in a fluoroscopic image to determine a rotational alignment of the catheters and may rotate the catheters until alignment is achieved. When the catheters are viewed as axially aligned based on the position of the rotational indicators or another portion of the catheters, the user may bring the catheters into close approximation.
Once the catheters are aligned, one or more adhesion elements may be activated to adhere tissue in vessels. As shown in
The adhesion elements may adhere tissue by heating the tissue. In some variations, the adhesion elements may heat tissue by delivering radiofrequency energy. In other variations, the adhesion elements may be heated through ohmic heating, which may in turn heat tissue. In yet other variations, the adhesion elements may deliver laser energy to heat tissue, or may deliver ultrasonic energy to heat tissue.
In some variations, the systems discussed herein may comprise an electrosurgical controller coupled to one or more adhesion elements for controlling tissue adhesion. A controller may control the energy delivery to one more adhesion elements to heat tissue based on the selected adhesion parameters. Adhesion parameters may include an energy waveform shape, frequency, amplitude, duration, and so forth. For example, in one non-limiting variation, a controller may be configured to deliver a waveform having a frequency between about 300 kHz and about 500 kHz, with a peak voltage of between about 120 V and about 140 V. In some variations, a controller may be configured to deliver a waveform having a frequency of about 400 kHz, with a peak voltage of about 130 V. The waveform may have any suitable shape, such as a sinusoidal or square shape. The controller may modulate one or more parameters to achieve a desired heating profile. For example, the controller may modulate one or more of the peak voltage or duty cycle of the waveform. In some variations, the electrosurgical controller may deliver energy for a predetermined duration to achieve the intended adhesion. In other variations, the strength of an adhesion cycle may be limited in power and/or duration so as to perform a plurality of adhesion cycles. In this manner, the thermal effects of heating may be dispersed over a longer period of time so as to limit collateral thermal injury to the vessel.
In some variations, tissue parameters may be measured and analyzed in order to determine one or more adhesion parameters. The electrosurgical controller may in some instances monitor the impedance during energy delivery to determine a rate of tissue heating. In other instances, termination of adhesion may occur after measuring a predetermined impedance or a predetermined rate of change of impedance. In order to measure impedance, the system may comprise an impedance metering circuit such as a bipolar sensing circuit with each adhesion element serving as an element. To measure impedance, low power DC or alternating voltage may be applied to the adhesion elements. The resulting current and/or phase may then be measured to determine impedance. Additionally or alternatively, impedance may also be measured during a thermal adhesion period by measuring the impedance in a bipolar or monopolar circuit. In this manner, a single heating cycle may be performed without interrupting the energy delivery cycle to measure impedance. Impedances measured before, after, and/or during an adhesion sequence may determine the level of vessel modification provided. Additionally or alternatively, a catheter may further comprise a thermocouple or thermistor to monitor tissue temperature as an additional input signal for controlling adhesion by the electrosurgical controller. In some variations, one or more impedance measurements or tissue temperature measurements may be outputted to a user as one or more of visual and audio feedback. For example, the system may output an impedance value on a display meter coupled to the catheters. Impedance values may be output as audio tones. In other variations, impedance measurements or tissue temperature information may be provided to the electrosurgical controller to automatically adjust or stop current delivery. For example, tissue measurements indicating that the temperature has reached 70° C. may indicate that protein denaturation has been achieved.
After tissue adhesion is performed using one or more adhesion elements, in some variations a fenestration between the two tubular structures may optionally be formed. In some variations, a fenestration may be formed using different devices, such as a different catheter system For example, a fistula between the two vessels may be formed using a system and method as described in U.S. patent application Ser. No. 13/298,169, filed on Nov. 16, 2011, and titled “DEVICES AND METHODS FOR FORMING A FISTULA,” and in U.S. patent application Ser. No. 15/406,755, filed Jan. 15, 2017, titled “DEVICES AND METHODS FOR FORMING A FISTULA” and claiming the benefit of U.S. Provisional Application No. 62/399,471, filed Sep. 25, 2016, and U.S. Provisional Application No. 62/279,603, filed Jan. 15, 2016, each of which was previously incorporated by reference in its entirety. For example, a fistula may be formed using a system comprising a first catheter and a second catheter. The first catheter may comprise a catheter body, one or more magnetic elements, and a fistula-forming element. The second catheter may comprise a catheter body, one or more magnetic elements, and may optionally comprise a fistula-forming element. In some variations, the fistula-forming element may comprise an electrode configured to move between a low-profile configuration and an extended configuration in which it extends radially away from the catheter body. In some variations the fistula-forming element may be spring-biased toward the extended configuration, i.e., may be configured to self-expand from the low-profile to the extended configuration, and may be held in the low-profile configuration during placement, for example by an external radially inward force on the electrode from a the catheter body or a vessel wall during delivery.
In other variations, a fenestration may be formed using the same catheters but using a separate fistula-forming element. For example, the separate fistula-forming element may be axially displaced along the catheter from the adhesion element, or as another example, a separate fistula-forming element may be located within an adhesion element. In the case of a fistula formed between blood vessels, hemostasis may be created without the need for a separate device or structure (e.g., a suture, stent, shunt, or the like) connecting or joining the blood vessels. In yet other variations, a fenestration may be formed by further activating the adhesion elements to bore through, perforate, or otherwise create a passageway between the two structures (e.g., blood vessels such that blood may flow directly between the two adjoining blood vessels). In some variations in which a fenestration is formed, a first current may be applied to the adhesion element to adhere tissue together while a second current may be applied to form an opening through the tissue in the shape of the adhesion element. For example, the waveform may be modified to have an increased peak voltage. For example, the peak voltage may be increased to reach an ionization threshold. In one non-limiting example, the peak voltage may be increased to about 180 V. In other variations, energy supplied to an adhesion element for a first time period may adhere the two vessels together while continued heating for a second time period beyond the first time period may form a fistula. In one non-limiting example, the first time period may be up to about 10 seconds, while the second time period may be up to an additional about 5 seconds.
In variations in which a fistula is formed between the two vessels after adhesion, the weld may maintain adhesion of the two attached vessels when the fistula is subsequently formed in the weld. In other words, a weld may prevent pressurized fluids traveling through the fistula from breaching the hermetic seal. In this way, the weld may prevent extravasation or leaking of fluids and thus may provide an enhanced fistula.
Although the foregoing variations have, for the purposes of clarity and understanding, been described in some detail by of illustration and example, it will be apparent that certain changes and modifications may be practiced, and are intended to fall within the scope of the appended claims. Additionally, it should be understood that the components and characteristics of the devices and methods described herein may be used in any appropriate combination. The description of certain elements or characteristics with respect to a specific figure are not intended to be limiting or nor should they be interpreted to suggest that the element cannot be used in combination with any of the other described elements.
This application is a continuation of International Application No. PCT/US2017/013611, filed Jan. 15, 2017, which claims the benefit of U.S. Provisional Application No. 62/279,642, filed Jan. 15, 2016, and titled “SYSTEMS AND METHODS FOR ADHERING VESSELS,” each of which is hereby incorporated by reference in its entirety.
Number | Name | Date | Kind |
---|---|---|---|
3649850 | Davis | Mar 1972 | A |
3827436 | Stumpf et al. | Aug 1974 | A |
4416664 | Womack | Nov 1983 | A |
4802475 | Weshahy | Feb 1989 | A |
5313943 | Houser et al. | May 1994 | A |
5383460 | Jang et al. | Jan 1995 | A |
5429131 | Scheinman | Jul 1995 | A |
5697909 | Eggers et al. | Dec 1997 | A |
5782239 | Webster, Jr. | Jul 1998 | A |
5800487 | Mikus et al. | Sep 1998 | A |
5830222 | Makower | Nov 1998 | A |
5830224 | Cohn et al. | Nov 1998 | A |
5836947 | Fleischman et al. | Nov 1998 | A |
5895404 | Ruiz | Apr 1999 | A |
5971979 | Joye et al. | Oct 1999 | A |
6004330 | Middleman et al. | Dec 1999 | A |
6032677 | Blechman et al. | Mar 2000 | A |
6039730 | Rabin et al. | Mar 2000 | A |
6068638 | Makower | May 2000 | A |
6071274 | Thompson et al. | Jun 2000 | A |
6099542 | Cohn et al. | Aug 2000 | A |
6159225 | Makower | Dec 2000 | A |
6190353 | Makower et al. | Feb 2001 | B1 |
6197025 | Grossi et al. | Mar 2001 | B1 |
6217575 | DeVore et al. | Apr 2001 | B1 |
6231587 | Makower | May 2001 | B1 |
6256525 | Yang et al. | Jul 2001 | B1 |
6280440 | Gocho | Aug 2001 | B1 |
6283988 | Laufer et al. | Sep 2001 | B1 |
6287306 | Kroll et al. | Sep 2001 | B1 |
6302875 | Makower et al. | Oct 2001 | B1 |
6327505 | Medhkour et al. | Dec 2001 | B1 |
6347247 | Dev et al. | Feb 2002 | B1 |
6355029 | Joye et al. | Mar 2002 | B1 |
6357447 | Swanson et al. | Mar 2002 | B1 |
6379353 | Nichols | Apr 2002 | B1 |
6383180 | Lalonde et al. | May 2002 | B1 |
6394956 | Chandrasekaran et al. | May 2002 | B1 |
6400976 | Champeau | Jun 2002 | B1 |
6428534 | Joye et al. | Aug 2002 | B1 |
6461356 | Patterson | Oct 2002 | B1 |
6464665 | Heuser | Oct 2002 | B1 |
6464723 | Callol | Oct 2002 | B1 |
6468268 | Abboud et al. | Oct 2002 | B1 |
6475214 | Moaddeb | Nov 2002 | B1 |
6475226 | Belef et al. | Nov 2002 | B1 |
6527724 | Fenici | Mar 2003 | B1 |
6527769 | Langberg et al. | Mar 2003 | B2 |
6542766 | Hall et al. | Apr 2003 | B2 |
6544230 | Flaherty et al. | Apr 2003 | B1 |
6569158 | Abboud et al. | May 2003 | B1 |
6569162 | He | May 2003 | B2 |
6579311 | Makower | Jun 2003 | B1 |
6585650 | Solem | Jul 2003 | B1 |
6592577 | Abboud et al. | Jul 2003 | B2 |
6629987 | Gambale et al. | Oct 2003 | B1 |
6635053 | Lalonde et al. | Oct 2003 | B1 |
6655386 | Makower et al. | Dec 2003 | B1 |
6656173 | Palermo | Dec 2003 | B1 |
6663625 | Ormsby et al. | Dec 2003 | B1 |
6669709 | Cohn et al. | Dec 2003 | B1 |
6673085 | Berg | Jan 2004 | B1 |
6676657 | Wood | Jan 2004 | B2 |
6682525 | Lalonde et al. | Jan 2004 | B2 |
6695878 | McGuckin et al. | Feb 2004 | B2 |
6709444 | Makower | Mar 2004 | B1 |
6719756 | Muntermann | Apr 2004 | B1 |
6726697 | Nicholas et al. | Apr 2004 | B2 |
6733494 | Abboud et al. | May 2004 | B2 |
6736808 | Motamedi et al. | May 2004 | B1 |
6761708 | Chiu et al. | Jul 2004 | B1 |
6761714 | Abboud et al. | Jul 2004 | B2 |
6780181 | Kroll et al. | Aug 2004 | B2 |
6849073 | Hoey et al. | Feb 2005 | B2 |
6855143 | Davison et al. | Feb 2005 | B2 |
6887234 | Abboud et al. | May 2005 | B2 |
6911026 | Hall et al. | Jun 2005 | B1 |
6932814 | Wood | Aug 2005 | B2 |
6936024 | Houser | Aug 2005 | B1 |
6960209 | Clague et al. | Nov 2005 | B2 |
6971983 | Cancio | Dec 2005 | B1 |
6981972 | Farley et al. | Jan 2006 | B1 |
7059330 | Makower et al. | Jun 2006 | B1 |
7060063 | Marion et al. | Jun 2006 | B2 |
7094235 | Francischelli | Aug 2006 | B2 |
7155293 | Westlund et al. | Dec 2006 | B2 |
7179270 | Makower | Feb 2007 | B2 |
7189231 | Clague et al. | Mar 2007 | B2 |
7214234 | Rapacki et al. | May 2007 | B2 |
7231260 | Wallace et al. | Jun 2007 | B2 |
7250051 | Francischelli | Jul 2007 | B2 |
7288075 | Parihar et al. | Oct 2007 | B2 |
7303554 | Lalonde et al. | Dec 2007 | B2 |
7306598 | Truckai et al. | Dec 2007 | B2 |
7335198 | Eggers et al. | Feb 2008 | B2 |
7341063 | Garbibaldi et al. | Mar 2008 | B2 |
7367341 | Anderson et al. | May 2008 | B2 |
7374567 | Heuser | May 2008 | B2 |
7387636 | Cohn et al. | Jun 2008 | B2 |
7407506 | Makower | Aug 2008 | B2 |
7522950 | Fuimaono et al. | Apr 2009 | B2 |
7628768 | Faul et al. | Dec 2009 | B2 |
7702387 | Stevenson et al. | Apr 2010 | B2 |
7727268 | Cunniffe et al. | Jun 2010 | B2 |
7744596 | Young et al. | Jun 2010 | B2 |
7811281 | Rentrop | Oct 2010 | B1 |
7828814 | Brenneman et al. | Nov 2010 | B2 |
7846172 | Makower | Dec 2010 | B2 |
7849860 | Makower et al. | Dec 2010 | B2 |
7857809 | Drysen | Dec 2010 | B2 |
7881797 | Griffin et al. | Feb 2011 | B2 |
7955326 | Paul et al. | Jun 2011 | B2 |
7967769 | Faul et al. | Jun 2011 | B2 |
7967770 | Li et al. | Jun 2011 | B2 |
8010208 | Nimer et al. | Aug 2011 | B2 |
8048016 | Faul et al. | Nov 2011 | B2 |
8052680 | Hassett et al. | Nov 2011 | B2 |
8062321 | Heuser et al. | Nov 2011 | B2 |
RE43007 | Lalonde et al. | Dec 2011 | E |
8075555 | Truckai et al. | Dec 2011 | B2 |
8088171 | Brenneman | Jan 2012 | B2 |
8100899 | Doty et al. | Jan 2012 | B2 |
8118809 | Paul et al. | Feb 2012 | B2 |
8135467 | Markowitz et al. | Mar 2012 | B2 |
8142454 | Harrison et al. | Mar 2012 | B2 |
8192425 | Mirza et al. | Jun 2012 | B2 |
8200466 | Spilker et al. | Jun 2012 | B2 |
8226592 | Brenneman et al. | Jul 2012 | B2 |
8231618 | Viswanathan et al. | Jul 2012 | B2 |
8236014 | Brenneman et al. | Aug 2012 | B2 |
8262649 | Francischelli | Sep 2012 | B2 |
8273095 | Brenneman et al. | Sep 2012 | B2 |
8328797 | Wilson et al. | Dec 2012 | B2 |
8333758 | Joye et al. | Dec 2012 | B2 |
8361061 | Esch et al. | Jan 2013 | B2 |
8366707 | Kassab et al. | Feb 2013 | B2 |
8382697 | Brenneman et al. | Feb 2013 | B2 |
8409196 | Durgin et al. | Apr 2013 | B2 |
8413664 | Appling | Apr 2013 | B2 |
8414572 | Davison et al. | Apr 2013 | B2 |
8419681 | Sell | Apr 2013 | B2 |
8439909 | Wang et al. | May 2013 | B2 |
8454587 | Lalonde et al. | Jun 2013 | B2 |
8475441 | Babkin et al. | Jul 2013 | B2 |
8486062 | Belhe et al. | Jul 2013 | B2 |
8486064 | Van Wyk et al. | Jul 2013 | B2 |
8551032 | Faul et al. | Oct 2013 | B2 |
8574185 | Faul et al. | Nov 2013 | B2 |
8585700 | Katou | Nov 2013 | B2 |
8608754 | Wensel et al. | Dec 2013 | B2 |
8641724 | Brenneman et al. | Feb 2014 | B2 |
8649879 | DiGiore et al. | Feb 2014 | B2 |
8676309 | Deem et al. | Mar 2014 | B2 |
8685014 | Babkin et al. | Apr 2014 | B2 |
8700179 | Pianca et al. | Apr 2014 | B2 |
8715281 | Barlow et al. | May 2014 | B2 |
8758334 | Coe et al. | Jun 2014 | B2 |
8771267 | Kunis et al. | Jul 2014 | B2 |
8784409 | Robilotto et al. | Jul 2014 | B2 |
8790341 | Pappone et al. | Jul 2014 | B2 |
8876699 | Sato et al. | Nov 2014 | B2 |
8876815 | Coe et al. | Nov 2014 | B2 |
8882765 | Kassab et al. | Nov 2014 | B2 |
8911435 | Katoh et al. | Dec 2014 | B2 |
8951251 | Willard | Feb 2015 | B2 |
9017323 | Miller et al. | Apr 2015 | B2 |
9039702 | Miller et al. | May 2015 | B2 |
9072880 | Phillips et al. | Jul 2015 | B2 |
9089316 | Baust et al. | Jul 2015 | B2 |
9108018 | Dickinson et al. | Aug 2015 | B2 |
9155827 | Franano | Oct 2015 | B2 |
9204916 | Lalonde | Dec 2015 | B2 |
9259340 | Heuser et al. | Feb 2016 | B2 |
9283034 | Katoh et al. | Mar 2016 | B2 |
9307992 | Wilson et al. | Apr 2016 | B2 |
9314329 | Dickinson et al. | Apr 2016 | B2 |
9326792 | Dickinson et al. | May 2016 | B2 |
9364280 | Zarins et al. | Jun 2016 | B2 |
9402560 | Organ et al. | Aug 2016 | B2 |
9414885 | Willard | Aug 2016 | B2 |
9439728 | Hull et al. | Sep 2016 | B2 |
9445868 | Hull et al. | Sep 2016 | B2 |
9452015 | Kellerman et al. | Sep 2016 | B2 |
9486276 | Rios et al. | Nov 2016 | B2 |
9510901 | Steinke et al. | Dec 2016 | B2 |
9623217 | Pillai | Apr 2017 | B2 |
9706998 | Dickinson et al. | Jul 2017 | B2 |
9782201 | Dickinson et al. | Oct 2017 | B2 |
9782533 | Brenneman et al. | Oct 2017 | B2 |
10045817 | Miller et al. | Aug 2018 | B2 |
10265206 | Heuser et al. | Apr 2019 | B2 |
10517637 | Dickinson et al. | Dec 2019 | B2 |
10543308 | Lenihan et al. | Jan 2020 | B2 |
10575974 | De Pablo Peña et al. | Mar 2020 | B2 |
10596356 | Lenihan et al. | Mar 2020 | B2 |
20010029384 | Nicholas et al. | Oct 2001 | A1 |
20020072739 | Lee et al. | Jun 2002 | A1 |
20020113678 | Creighton | Aug 2002 | A1 |
20020151945 | Gobin et al. | Oct 2002 | A1 |
20030009163 | Messing et al. | Jan 2003 | A1 |
20030220674 | Anderson et al. | Nov 2003 | A1 |
20040059211 | Patel et al. | Mar 2004 | A1 |
20040059280 | Makower et al. | Mar 2004 | A1 |
20040098095 | Burnside et al. | May 2004 | A1 |
20040167506 | Chen | Aug 2004 | A1 |
20040215220 | Dolan et al. | Oct 2004 | A1 |
20040236360 | Cohn et al. | Nov 2004 | A1 |
20050033401 | Cunniffe et al. | Feb 2005 | A1 |
20050065509 | Coldwell et al. | Mar 2005 | A1 |
20050245925 | Iki et al. | Nov 2005 | A1 |
20050251120 | Anderson et al. | Nov 2005 | A1 |
20060079897 | Harrison et al. | Apr 2006 | A1 |
20060111704 | Brenneman et al. | May 2006 | A1 |
20070173878 | Heuser | Jul 2007 | A1 |
20070185567 | Heuser et al. | Aug 2007 | A1 |
20070203515 | Heuser et al. | Aug 2007 | A1 |
20070203572 | Heuser et al. | Aug 2007 | A1 |
20070293856 | Paul et al. | Dec 2007 | A1 |
20080021532 | Kveen et al. | Jan 2008 | A1 |
20080039830 | Munger | Feb 2008 | A1 |
20080051626 | Sato et al. | Feb 2008 | A1 |
20080065019 | Heuser et al. | Mar 2008 | A1 |
20080091192 | Paul et al. | Apr 2008 | A1 |
20080119879 | Brenneman | May 2008 | A1 |
20080140061 | Toubia et al. | Jun 2008 | A1 |
20080161901 | Heuser et al. | Jul 2008 | A1 |
20080171944 | Brenneman et al. | Jul 2008 | A1 |
20080183164 | Elkins et al. | Jul 2008 | A1 |
20080188848 | Deutmeyer et al. | Aug 2008 | A1 |
20080221519 | Schwach et al. | Sep 2008 | A1 |
20080275442 | Paul et al. | Nov 2008 | A1 |
20080312577 | Drasler et al. | Dec 2008 | A1 |
20090036872 | Fitzgerald et al. | Feb 2009 | A1 |
20090076324 | Takayama et al. | Mar 2009 | A1 |
20090093791 | Heuser | Apr 2009 | A1 |
20090112119 | Kim | Apr 2009 | A1 |
20090118722 | Ebbers et al. | May 2009 | A1 |
20090124847 | Doty | May 2009 | A1 |
20090157014 | Osborne et al. | Jun 2009 | A1 |
20090187098 | Makower et al. | Jul 2009 | A1 |
20090198232 | Young et al. | Aug 2009 | A1 |
20090248148 | Shaolian et al. | Oct 2009 | A1 |
20090275876 | Brenneman et al. | Nov 2009 | A1 |
20090281379 | Binmoeller et al. | Nov 2009 | A1 |
20090318849 | Hobbs et al. | Dec 2009 | A1 |
20100004623 | Hamilton, Jr. et al. | Jan 2010 | A1 |
20100010488 | Kassab et al. | Jan 2010 | A1 |
20100082058 | Kassab | Apr 2010 | A1 |
20100130835 | Brenneman et al. | May 2010 | A1 |
20100198206 | Levin | Aug 2010 | A1 |
20100204691 | Bencini | Aug 2010 | A1 |
20100222664 | Lemon et al. | Sep 2010 | A1 |
20100256616 | Katoh et al. | Oct 2010 | A1 |
20100280316 | Dietz et al. | Nov 2010 | A1 |
20100280514 | Zerfas et al. | Nov 2010 | A1 |
20100286705 | Vassiliades, Jr. | Nov 2010 | A1 |
20100292685 | Katoh et al. | Nov 2010 | A1 |
20100298645 | Deutch | Nov 2010 | A1 |
20100318180 | Porter | Dec 2010 | A1 |
20110015657 | Brenneman et al. | Jan 2011 | A1 |
20110112427 | Phillips et al. | May 2011 | A1 |
20110118735 | Abou-Marie et al. | May 2011 | A1 |
20110201990 | Franano | Aug 2011 | A1 |
20110213309 | Young et al. | Sep 2011 | A1 |
20110218476 | Kraemer et al. | Sep 2011 | A1 |
20110270149 | Faul et al. | Nov 2011 | A1 |
20110288392 | de la Rama et al. | Nov 2011 | A1 |
20110288544 | Verin et al. | Nov 2011 | A1 |
20110306959 | Kellerman | Dec 2011 | A1 |
20110306993 | Hull | Dec 2011 | A1 |
20110319976 | Iyer et al. | Dec 2011 | A1 |
20120010556 | Faul et al. | Jan 2012 | A1 |
20120022518 | Levinson | Jan 2012 | A1 |
20120035539 | Tegg | Feb 2012 | A1 |
20120046678 | LeMaitre et al. | Feb 2012 | A1 |
20120059398 | Pate et al. | Mar 2012 | A1 |
20120065652 | Cully et al. | Mar 2012 | A1 |
20120078342 | Vollkron et al. | Mar 2012 | A1 |
20120089123 | Organ et al. | Apr 2012 | A1 |
20120101423 | Brenneman | Apr 2012 | A1 |
20120116354 | Heuser | May 2012 | A1 |
20120157992 | Smith et al. | Jun 2012 | A1 |
20120209377 | MacHold et al. | Aug 2012 | A1 |
20120215088 | Wang et al. | Aug 2012 | A1 |
20120239021 | Doty et al. | Sep 2012 | A1 |
20120277736 | Francischelli | Nov 2012 | A1 |
20120281330 | Abbott et al. | Nov 2012 | A1 |
20120289953 | Berzak et al. | Nov 2012 | A1 |
20120296262 | Ogata et al. | Nov 2012 | A1 |
20120302935 | Miller | Nov 2012 | A1 |
20130041306 | Faul et al. | Feb 2013 | A1 |
20130056876 | Harvey et al. | Mar 2013 | A1 |
20130110105 | Vankov | May 2013 | A1 |
20130172881 | Hill et al. | Jul 2013 | A1 |
20130190744 | Avram et al. | Jul 2013 | A1 |
20130190754 | Paul et al. | Jul 2013 | A1 |
20130216351 | Griffin | Aug 2013 | A1 |
20130226170 | Seddon et al. | Aug 2013 | A1 |
20130261368 | Schwartz | Oct 2013 | A1 |
20130282000 | Parsonage | Oct 2013 | A1 |
20130296704 | Magnin et al. | Nov 2013 | A1 |
20140012251 | Himmelstein et al. | Jan 2014 | A1 |
20140031674 | Newman et al. | Jan 2014 | A1 |
20140094791 | Hull et al. | Apr 2014 | A1 |
20140100557 | Bohner et al. | Apr 2014 | A1 |
20140100562 | Sutermeister et al. | Apr 2014 | A1 |
20140107642 | Rios | Apr 2014 | A1 |
20140166098 | Kian et al. | Jun 2014 | A1 |
20140188028 | Brenneman et al. | Jul 2014 | A1 |
20140276335 | Pate | Sep 2014 | A1 |
20150005759 | Welches | Jan 2015 | A1 |
20150011909 | Holmin et al. | Jan 2015 | A1 |
20150018810 | Baust et al. | Jan 2015 | A1 |
20150057654 | Leung et al. | Feb 2015 | A1 |
20150057687 | Gittard | Feb 2015 | A1 |
20150080886 | Miller et al. | Mar 2015 | A1 |
20150094645 | Omar-Pasha | Apr 2015 | A1 |
20150112195 | Berger et al. | Apr 2015 | A1 |
20150126965 | Liungman | May 2015 | A1 |
20150134055 | Spence et al. | May 2015 | A1 |
20150141836 | Naumann et al. | May 2015 | A1 |
20150164573 | Delaney | Jun 2015 | A1 |
20150196309 | Matsubara et al. | Jul 2015 | A1 |
20150196356 | Kauphusman et al. | Jul 2015 | A1 |
20150196360 | Grantham et al. | Jul 2015 | A1 |
20150201962 | Kellerman et al. | Jul 2015 | A1 |
20150258308 | Pate | Sep 2015 | A1 |
20150297259 | Matsubara et al. | Oct 2015 | A1 |
20150313668 | Miller et al. | Nov 2015 | A1 |
20150320472 | Ghaffari et al. | Nov 2015 | A1 |
20160022345 | Baust et al. | Jan 2016 | A1 |
20160051323 | Stigall et al. | Feb 2016 | A1 |
20160058452 | Brenneman et al. | Mar 2016 | A1 |
20160058956 | Cohn et al. | Mar 2016 | A1 |
20160067449 | Misener et al. | Mar 2016 | A1 |
20160082234 | Schwartz et al. | Mar 2016 | A1 |
20160100840 | Brenneman et al. | Apr 2016 | A1 |
20160128855 | Heuser et al. | May 2016 | A1 |
20160135881 | Katoh et al. | May 2016 | A1 |
20160184011 | Krishnan | Jun 2016 | A1 |
20160206317 | Dickinson et al. | Jul 2016 | A1 |
20170071627 | Kellerman et al. | Mar 2017 | A1 |
20170119464 | Rios et al. | May 2017 | A1 |
20170172679 | Doty et al. | Jun 2017 | A1 |
20170202603 | Cohn et al. | Jul 2017 | A1 |
20170202616 | Pate et al. | Jul 2017 | A1 |
20170232272 | Perkins et al. | Aug 2017 | A1 |
20170252006 | Tsuruno | Sep 2017 | A1 |
20180000512 | Dickinson et al. | Jan 2018 | A1 |
20180083228 | Yang et al. | Mar 2018 | A1 |
20180116522 | Brenneman et al. | May 2018 | A1 |
20180206845 | Brenneman et al. | Jul 2018 | A1 |
20180344396 | Miller et al. | Dec 2018 | A1 |
20200038103 | Pappone et al. | Feb 2020 | A1 |
20200061338 | Pate | Feb 2020 | A1 |
20200178970 | Berman et al. | Jun 2020 | A1 |
Number | Date | Country |
---|---|---|
2883209 | Apr 2014 | CA |
1730123 | Feb 2006 | CN |
101730557 | Jun 2010 | CN |
0923912 | Jun 1999 | EP |
11514269 | Dec 1999 | JP |
3127126 | Nov 2006 | JP |
2009545338 | Dec 2009 | JP |
2014500072 | Jan 2014 | JP |
2168951 | Jun 2001 | RU |
9713463 | Apr 1997 | WO |
9729682 | Aug 1997 | WO |
9956640 | Nov 1999 | WO |
2006105008 | Oct 2006 | WO |
2008010039 | Jan 2008 | WO |
2009005644 | Jan 2009 | WO |
2011100625 | Aug 2011 | WO |
2012068273 | May 2012 | WO |
WO-2013112584 | Aug 2013 | WO |
2014028306 | Feb 2014 | WO |
2014052919 | Apr 2014 | WO |
2015061614 | Apr 2015 | WO |
2015085119 | Jun 2015 | WO |
2015108984 | Jul 2015 | WO |
2016033380 | Mar 2016 | WO |
2016081321 | May 2016 | WO |
2017124059 | Jul 2017 | WO |
2017124060 | Jul 2017 | WO |
2018057095 | Mar 2018 | WO |
Entry |
---|
International Search Report and Written Opinion pertaining to PCT/US2019/034896, mailed May 12, 2020. |
Maybury et al., “The Effect of Roll Angle on the Performance of Halbach Arrays,” University of California-San Diego, Center for Magnetic Recording Research (2008), 19 pgs. |
Choi, et al., Design of a Halbach Magnet Array Based on Optimization Techniques; IEEE Transactions on Magnetics, vol. 44, No. 10, Oct. 2008, pp. 2361-2366. (Year: 2008). |
“Banasik et al. (2011).” “A rare variant route of the ulnar artery does not contraindicate the creation of a fistula in the wrist of a diabetic patient with end-stage renal disease,” “Postepy Hig Med Dosw. 65:654-657.” |
Bharat et al. (2012). “A novel technique of vascular anastomosis to prevent juxta-anastomotic stenosis following arteriovenous fistula creation,” J. Vascular Surgery 55(1):274-280. |
Bode et al. (2011 ). “Clinical study protocol for the arch project Computational modeling for improvement of outcome after vascular access creation,” J. Vase. Access 12(4):369-376. |
Hakim et al., “Ulnar artery-based free forearm flap: Review of Specific anatomic features in 322 cases and related literature,” Heand & Neck, Dec. 2013 (published online:2014), Wiley Online Library. |
Davidson, I. et al. (2008). “Duplex Ultrasound Evaluation for Dialysis Access Selection and Maintenance: A Practical Guide,” The Journal of Vascular Access 9(1 ): 1-9. |
Gracz, et al. (1977). “Proximal forearm fistula for maintenance hemodialysis,” Kidney International 11 :71-75. |
Jennings, WC. et al. (2011). “Primary arteriovenous fistula inflow proximalization for patients at high risk for dialysis access-associated ischemic steal syndrome,” J. Vase. Surgery 54(2):554-558. |
Kinnaert, et al. (1971). “Ulnar Arteriovenous Fistula for Maintenance Haemodial Ysis,” British J. Surgery 58(9):641-643. |
Morale et al. (2011). “Venae comitantes as a potential vascular resource to create native arteriovenous fistulae,” J. Vase. Access 12(3):211-214. |
Shenoy, S. (2009). “Surgical anatomy of upper arm: what is needed for AVF planning,” The Journal of Vascular Access 10:223-232. |
Vachharajani, T. (2010). “Atlas of Dialysis Vascular Access,” Wake Forest University School of Medicine, 77 total pages. |
Whittaker et al. (2011). “Prevention better than cure. Avoiding steal syndrome with proximal radial or ulnar arteriovenous fistulae” J. Vase. Access 12(4):318-320. |
Office Action pertaining to corresponding Japanese Patent Application No. 2018-536423, dated Feb. 12, 2021. |
Extended European Search Report pertaining to EP Patent Application No. 17853586.0, dated Apr. 29, 2020. |
Extended European Search Report for EP Application No. 17739123.2. |
Office Action dated Jun. 4, 2021, pertaining to Japanese Patent Application No. 2019-516190. |
Office Action dated Dec. 23, 2022, pertaining to Chinese Patent Application No. 201780017044.7. |
Office Action, dated Feb. 9, 2023, pertaining to Brazil Patent Application No. BR112018014010-4. |
Number | Date | Country | |
---|---|---|---|
20190133678 A1 | May 2019 | US |
Number | Date | Country | |
---|---|---|---|
62279642 | Jan 2016 | US |
Number | Date | Country | |
---|---|---|---|
Parent | PCT/US2017/013611 | Jan 2017 | WO |
Child | 16024241 | US |